WO2000069833A1 - Anticoagulants a base d'uracils d'aryle polycycliques et d'heteroaryles - Google Patents
Anticoagulants a base d'uracils d'aryle polycycliques et d'heteroaryles Download PDFInfo
- Publication number
- WO2000069833A1 WO2000069833A1 PCT/US2000/008226 US0008226W WO0069833A1 WO 2000069833 A1 WO2000069833 A1 WO 2000069833A1 US 0008226 W US0008226 W US 0008226W WO 0069833 A1 WO0069833 A1 WO 0069833A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- carbon
- hydrido
- amino
- hydroxy
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 title claims description 49
- 239000003146 anticoagulant agent Substances 0.000 title abstract description 8
- -1 heteroaryl uracil compounds Chemical class 0.000 claims abstract description 1636
- 150000001875 compounds Chemical class 0.000 claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 230000001732 thrombotic effect Effects 0.000 claims abstract description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 672
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 509
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 222
- 229910052757 nitrogen Inorganic materials 0.000 claims description 216
- 125000000217 alkyl group Chemical group 0.000 claims description 207
- 229910052760 oxygen Inorganic materials 0.000 claims description 205
- 125000004429 atom Chemical group 0.000 claims description 189
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 166
- 125000001188 haloalkyl group Chemical group 0.000 claims description 164
- 229910052717 sulfur Inorganic materials 0.000 claims description 161
- 125000001145 hydrido group Chemical group *[H] 0.000 claims description 151
- 125000005843 halogen group Chemical group 0.000 claims description 148
- 125000003282 alkyl amino group Chemical group 0.000 claims description 143
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 119
- 125000003545 alkoxy group Chemical group 0.000 claims description 118
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 95
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 94
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 88
- 125000004414 alkyl thio group Chemical group 0.000 claims description 87
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 87
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 71
- 125000000033 alkoxyamino group Chemical group 0.000 claims description 68
- 125000000623 heterocyclic group Chemical group 0.000 claims description 64
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 62
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 61
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 60
- 125000001153 fluoro group Chemical group F* 0.000 claims description 60
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 54
- 150000003839 salts Chemical class 0.000 claims description 50
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 49
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 48
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 47
- 125000003118 aryl group Chemical group 0.000 claims description 46
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 45
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 43
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 42
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 41
- 125000005518 carboxamido group Chemical group 0.000 claims description 40
- 125000003342 alkenyl group Chemical group 0.000 claims description 39
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims description 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 36
- 125000004995 haloalkylthio group Chemical group 0.000 claims description 36
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 35
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 35
- 125000004076 pyridyl group Chemical group 0.000 claims description 35
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims description 34
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims description 34
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 34
- 125000001246 bromo group Chemical group Br* 0.000 claims description 33
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 33
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 32
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 32
- 125000003435 aroyl group Chemical group 0.000 claims description 31
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 30
- 125000005422 alkyl sulfonamido group Chemical group 0.000 claims description 29
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 28
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 28
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 26
- 125000001424 substituent group Chemical group 0.000 claims description 26
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 25
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 25
- 125000000304 alkynyl group Chemical group 0.000 claims description 24
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 23
- 150000001721 carbon Chemical group 0.000 claims description 23
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 22
- LLAPDLPYIYKTGQ-UHFFFAOYSA-N 1-aminoethyl Chemical group C[CH]N LLAPDLPYIYKTGQ-UHFFFAOYSA-N 0.000 claims description 21
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims description 21
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 21
- 239000001301 oxygen Substances 0.000 claims description 21
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 20
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims description 20
- 239000011593 sulfur Substances 0.000 claims description 20
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 18
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 claims description 18
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 16
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 claims description 16
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 16
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 15
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 14
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 14
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 14
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 13
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 13
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 12
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 12
- 208000007536 Thrombosis Diseases 0.000 claims description 12
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 claims description 12
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 125000004665 trialkylsilyl group Chemical group 0.000 claims description 11
- 125000005466 alkylenyl group Chemical group 0.000 claims description 10
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 10
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 9
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 claims description 9
- 125000004423 acyloxy group Chemical group 0.000 claims description 8
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 7
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims description 7
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims description 7
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 7
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 7
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 7
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 6
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 claims description 5
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 claims description 5
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims description 5
- 150000001408 amides Chemical group 0.000 claims description 5
- 210000001772 blood platelet Anatomy 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 claims description 3
- 208000005189 Embolism Diseases 0.000 claims description 3
- 206010002388 Angina unstable Diseases 0.000 claims description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 2
- 206010014498 Embolic stroke Diseases 0.000 claims description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 2
- 208000007814 Unstable Angina Diseases 0.000 claims description 2
- 206010047249 Venous thrombosis Diseases 0.000 claims description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 2
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 claims 122
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 56
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 53
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 37
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 36
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 35
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 30
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 25
- 229930192474 thiophene Natural products 0.000 claims 23
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 19
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims 19
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 16
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 15
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 15
- 125000001589 carboacyl group Chemical group 0.000 claims 15
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 claims 14
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 14
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 14
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 14
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 13
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 claims 13
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 13
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 12
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims 12
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 12
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 12
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 12
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 12
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 12
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 11
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 11
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 11
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 11
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 10
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 10
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 10
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 10
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 10
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 9
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 9
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 8
- 125000004273 azetidin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])C1([H])* 0.000 claims 8
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims 8
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 8
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 8
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 8
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 8
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims 8
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 7
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 7
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 claims 7
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 6
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims 6
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims 5
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 5
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 5
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 claims 5
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 5
- 125000003974 3-carbamimidamidopropyl group Chemical group C(N)(=N)NCCC* 0.000 claims 5
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 claims 5
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 claims 5
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 claims 5
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 claims 5
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 5
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims 5
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 5
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 5
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 4
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 claims 4
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 4
- HUTNOYOBQPAKIA-UHFFFAOYSA-N 1h-pyrazin-2-one Chemical group OC1=CN=CC=N1 HUTNOYOBQPAKIA-UHFFFAOYSA-N 0.000 claims 3
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 claims 3
- 125000006040 2-hexenyl group Chemical group 0.000 claims 3
- 125000006029 2-methyl-2-butenyl group Chemical group 0.000 claims 3
- 125000006024 2-pentenyl group Chemical group 0.000 claims 3
- 125000006041 3-hexenyl group Chemical group 0.000 claims 3
- 125000006042 4-hexenyl group Chemical group 0.000 claims 3
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 3
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 3
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000001435 Thromboembolism Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000006074 1-ethyl-2-butenyl group Chemical group 0.000 claims 1
- 125000006048 1-methyl-2-pentenyl group Chemical group 0.000 claims 1
- 125000006052 1-methyl-3-pentenyl group Chemical group 0.000 claims 1
- 125000006031 2-methyl-3-butenyl group Chemical group 0.000 claims 1
- 125000006032 3-methyl-3-butenyl group Chemical group 0.000 claims 1
- 125000006043 5-hexenyl group Chemical group 0.000 claims 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical group C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims 1
- 230000001269 cardiogenic effect Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000002319 fibrinogen receptor antagonist Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 claims 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 claims 1
- 230000015271 coagulation Effects 0.000 abstract description 8
- 238000005345 coagulation Methods 0.000 abstract description 8
- 229940127219 anticoagulant drug Drugs 0.000 abstract description 5
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 4
- 208000029078 coronary artery disease Diseases 0.000 abstract description 4
- 210000004351 coronary vessel Anatomy 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 108010022999 Serine Proteases Proteins 0.000 abstract description 3
- 102000012479 Serine Proteases Human genes 0.000 abstract description 3
- 239000003112 inhibitor Substances 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 abstract description 2
- 125000006850 spacer group Chemical group 0.000 description 57
- 125000000392 cycloalkenyl group Chemical group 0.000 description 33
- 125000002252 acyl group Chemical group 0.000 description 29
- 239000011669 selenium Substances 0.000 description 28
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 17
- 125000005326 heteroaryloxy alkyl group Chemical group 0.000 description 14
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 11
- 125000004687 alkyl sulfinyl alkyl group Chemical group 0.000 description 10
- 125000005164 aryl thioalkyl group Chemical group 0.000 description 10
- 125000005347 halocycloalkyl group Chemical group 0.000 description 10
- 108010073385 Fibrin Proteins 0.000 description 9
- 102000009123 Fibrin Human genes 0.000 description 9
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 9
- 229950003499 fibrin Drugs 0.000 description 9
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- 125000004104 aryloxy group Chemical group 0.000 description 8
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 description 8
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 206010053567 Coagulopathies Diseases 0.000 description 7
- 125000005452 alkenyloxyalkyl group Chemical group 0.000 description 7
- 125000001769 aryl amino group Chemical group 0.000 description 7
- 125000005110 aryl thio group Chemical group 0.000 description 7
- 230000035602 clotting Effects 0.000 description 7
- 125000006769 halocycloalkoxy group Chemical group 0.000 description 7
- 125000005241 heteroarylamino group Chemical group 0.000 description 7
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 7
- 125000002947 alkylene group Chemical group 0.000 description 6
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 6
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 5
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 5
- 108090000190 Thrombin Proteins 0.000 description 5
- 125000005354 acylalkyl group Chemical group 0.000 description 5
- 125000003302 alkenyloxy group Chemical group 0.000 description 5
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 5
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 5
- 239000003114 blood coagulation factor Substances 0.000 description 5
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 description 5
- 125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 description 5
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 125000004966 cyanoalkyl group Chemical group 0.000 description 4
- 125000005149 cycloalkylsulfinyl group Chemical group 0.000 description 4
- 125000005553 heteroaryloxy group Chemical group 0.000 description 4
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 description 4
- 125000005018 aryl alkenyl group Chemical group 0.000 description 3
- 125000005421 aryl sulfonamido group Chemical group 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 150000003857 carboxamides Chemical class 0.000 description 3
- 125000004465 cycloalkenyloxy group Chemical group 0.000 description 3
- 125000000000 cycloalkoxy group Chemical group 0.000 description 3
- 125000004858 cycloalkoxyalkyl group Chemical group 0.000 description 3
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 3
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000004441 haloalkylsulfonyl group Chemical group 0.000 description 3
- 125000004475 heteroaralkyl group Chemical group 0.000 description 3
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 3
- 125000005368 heteroarylthio group Chemical group 0.000 description 3
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 3
- 125000004468 heterocyclylthio group Chemical group 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- GHMVTBRBCJHSKM-UHFFFAOYSA-N [N].O=C1C=CNC(=O)N1 Chemical group [N].O=C1C=CNC(=O)N1 GHMVTBRBCJHSKM-UHFFFAOYSA-N 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000004967 formylalkyl group Chemical group 0.000 description 2
- 125000004440 haloalkylsulfinyl group Chemical group 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010074105 Factor Va Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000957333 Homo sapiens Muscleblind-like protein 3 Proteins 0.000 description 1
- 102100038751 Muscleblind-like protein 3 Human genes 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 206010043647 Thrombotic Stroke Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000005237 alkyleneamino group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940105772 coagulation factor vii Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000006624 extrinsic pathway Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 125000004963 sulfonylalkyl group Chemical group 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- This invention is in the field of anticoagulant therapy, and specifically relates to compounds, compositions and methods for preventing and treating thrombotic conditions such as coronary artery and cerebrovascular disease. More particularly, the invention relates to substituted polycyclic aryl and heteroaryl uracil compounds that inhibit serine proteases of the coagulation 10 cascade.
- Physiological systems control the fluidity of blood in mammals [Majerus, P. W. et al: Anticoagulant, Thrombolytic, and Antiplplatelet Drugs.
- platelets first adhere to macromolecules in subendothelian regions of an injured and/or damaged vessels. These platelets aggregate to form the primary hemostatic plug and stimulate local activation of plasma coagulation factors leading to generation of a fibrin clot that reinforces the aggregated platelets.
- Plasma coagulation factors include factors II, V, VII, VIII, IX, X, XI,
- protease zymogens 25 and XII; these are also called protease zymogens. These coagulation factors or protease zymogens are activated by serine proteases leading to coagulation in a so called “coagulation cascade” or chain reaction [Handin, R. I.: Bleeding and Thrombosis. In Wilson, J., et al. editors: Harrison's Principles of Internal Medicine. 12th Edition, New York, McGraw-Hill Book Co., 1991,p.350].
- Coagulation or clotting occurs in two ways through different pathways.
- An intrinsic or contact pathway leads from XII to Xiia to XIa to IXa and to the conversion of X to Xa.
- Xa with factor Va converts prothrombin (II) to thrombin (Ha) leading to conversion of fibrinogen to fibrin.
- Polymerization of fibrin leads to a fibrin clot.
- An extrinsic pathway is initiated by the conversion
- coagulation factor VII 35 of coagulation factor VII to Vila by Xa.
- Tissue Factor and Vila accelerates formation of Xa in the presence of calcium ion and phospholipids. Formation of Xa leads to thrombin, fibrin, and a fibrin clot as described above.
- the presence of one or more of these many different coagulation factors and two distinct pathways of clotting could enable the efficacious, selective control and better understanding of parts of the coagulation or clotting process.
- thrombosis results when platelet aggregation and/or a fibrin clot blocks (i.e., occludes) a blood vessel.
- Arterial thrombosis may result in ischemic necrosis of the tissue supplied by the artery.
- a myocardial infarction or heart attack can result.
- a thrombosis occurring in a vein may cause tissues drained by the vein to become edematous and inflamed.
- Thrombosis of a deep vein may be complicated by a pulmonary embolism.
- Preventing or treating clots in a blood vessel may be therapeutically useful by inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, inhibiting embolus formation, and for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels.
- the present invention relates to a class of compounds comprising Substituted Polycyclic Aryl and Heteroaryl uracils, which are beneficial in anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular disease, as given in Formula (I):
- J and J are independently selected from the group consisting of O and S;
- J is optionally selected from the group consisting of CH-R and N-R
- R is a linear spacer moiety having from 1 through 4 contiguous atoms linked to the point of bonding of a substituent selected from the group
- J is optionally selected from the group consisting of CH-R and N-R
- R is a linear spacer moiety having from 1 through 4 contiguous atoms linked to the point of bonding of a substituent selected from the group
- 4a 4b 14 15 consisting of R t , R , R , R and R to form a heterocyclyl ring having 5 through 8 contiguous members; a b J and J are optionally independently selected from the group
- J is optionally selected from the group consisting of CH-R and N-R
- R is a linear spacer moiety having from 1 through 4 contiguous atoms 39 40 linked to the points of bonding of both R and R to form a heterocyclyl ring having 5 through 8 contiguous members;
- D , D , J , J and K are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more than one can be a cov s
- K must be a covalent bond when two of D , D , J , J and K are O and S,
- R , R , R , R , and R are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;
- R are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, dialkylsulfonium, trialkylphosphonium, dialkylsulfoniumalkyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aryloylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, perhaloaralkyl, aralkyl sulfonyl, aralkylsulfonylalkyl, aralkylsulfinyl, aralkylsulfinylalkyl, halocycloalkyl, halocycloalkenyl, cycloalkylsulf
- R , R , R , R , R , R , and R are independently optionally h 16 19 h Q with the proviso that no more than one of R and R is Q at the same
- T R, 3 and _, R r, 33 , ⁇ R> 33 and , R T, , R. 3 and J r R, 35 , and , T R, 5 and , R, 3 6 are independently optionally selected to form a spacer pair wherein a spacer pair is taken together to form a linear moiety having from 3 through 6 contiguous atoms connecting the points of bonding of said spacer pair members to form a ring selected from the group consisting of a cycloalkenyl ring having 5 through 8 contiguous members, a partially saturated heterocyclyl ring having 5 through 8 contiguous members, a heteroaryl ring having 5 through 6 contiguous members, and an aryl with the proviso that no more than one of the group
- J T R, 6 are used , at th -.e same time;
- R and R , R and R , R and R , and R and R are independently optionally selected to form a spacer pair wherein a spacer pair is taken together to form a linear moiety having from 3 through 6 contiguous atoms connecting the points of bonding of said spacer pair members to form a ring selected from the group consisting of a cycloalkenyl ring having 5 through 8 contiguous members, a partially saturated heterocyclyl ring having 5 through 8 contiguous members, a heteroaryl ring having 5 through 6 contiguous members, and an aryl with the proviso that no more than one of the group consisting of spacer pairs R and R , R and R , R and R , and R
- 3 4 3 4 consisting of C, N, O, and S, no more than one of D , D , J , and J is O, no
- R , R , R , and R are N with the proviso that R , R , R , and R are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;
- B is optionally selected from the group consisting of hydrido, trialkylsilyl, C2-C8 alkyl, C3-C8 alkenyl, C3-C8 alkylenyl, C3-C8 alkynyl, C2-C8 haloalkyl, and C3-C8 haloalkenyl wherein each member of group B is optionally substituted at any carbon up to and including 6 atoms from the point of attachment of B to A with one or more of the group consisting of R32, R33,
- B is optionally selected from the group consisting of C3-C15 cycloalkyl, C5-C10 cycloalkenyl, C4-C12 saturated heterocyclyl, and C4-C9 partially saturated heterocyclyl, wherein each ring carbon is optionally
- a ring carbon other than the ring carbon at the point of attachment of B to A is optionally substituted with oxo provided that no more than one ring carbon is substituted by oxo at the same time, ring carbons and nitrogen adjacent to the carbon atom at the point of attachment are optionally
- R 33 optionally substituted with R , and a ring carbon or nitrogen four atoms from
- A is selected from the group consisting of single covalent bond
- W is selected from the group consisting of O, S, C(O), C(S), C(O)S, C(S)O, C(O)N(R 7 ), C(S)N(R ? ), (R ? )NC(O), (R ? )NC(S), S(O), S(O) 2 ,
- R and R are independently selected from the group consisting of hydrido, hydroxy, alkyl, alkenyl, aryl, aralkyl, aryloxy, alkoxy, alkenyloxy, alkylthio, alkylamino, arylthio, arylamino, acyl, aroyl, heteroaroyl, aralkoxyalkyl, heteroaralkoxyalkyl, , aryloxyalkyl, alkoxyalkyl, alkenyloxyalkyl, alkylthioalkyl, arylthioalkyl, aralkoxyalkyl, heteroaralkoxyalkyl, alkylsulfinylalkyl, alkylsulf onylalkyl, heteroaryl, heteroaryl oxy, heteroarylamino, heteroaralkyl, heteroaralkylamino, and heteroaryloxyalkyl;
- J J . R , R , R , R , R , R and R are independently selected from the group consisting of amidino, hydroxyamino, hydrido, hydroxy, halo, cyano, aryloxy, amino, alkylamino, dialkylamino, hydroxyalkyl, aminoalkyl, acyl, aroyl, heteroaroyl, heteroaryloxyalkyl, sulfhydryl, acylamido, alkoxy, alkylthio, arylthio, alkyl, alkenyl, alkynyl, aryl, aralkyl, aryloxyalkyl, aralkoxyalkylalkoxy, alkylsulfinylalkyl, alkylsulf onylalkyl, aralkylthioalkyl, heteroaralkoxythioalkyl, alkoxyalkyl,
- halocycloalkoxy halocycloalkoxy alkyl, halocycloalkenyloxyalkyl, saturated heterocyclyl, partially saturated heterocyclyl, heteroaryl, heteroarylalkyl, heteroarylthioalkyl, heteroaralkylthioalkyl, monocarboalkoxyalkyl, di carboalkoxyalkyl, monocyanoalkyl, dicyanoalkyl, carboalkoxycyanoalkyl, alkylsulfmyl, alkylsulf onyl, haloalkylsulfinyl.
- haloalkylsulfonyl arylsulfinyl, arylsulfinylalkyl, arylsulf onyl, arylsulf onylalkyl, aralkylsulfinyl, aralkylsulfonyl, cycloalkylsulfinyl, cycloalkylsulfonyl, cycloalkylsulfinylalkyl, cycloalkylsufonylalkyl, heteroarylsulfonylalkyl, heteroarylsulfinyl, heteroarylsulfonyl, heteroarylsulfinylalkyl, aralkylsulfinylalkyl, aralkylsulf onylalkyl, carboxy, carboxyalkyl, carboalkoxy, carboxamide, carboxamidoalkyl, carboaralkoxy, trialkyls
- R and R when bonded to different carbons, are optionally taken together to form a group selected from the group consisting of covalent bond, alkylene, haloalkylene, and a linear moiety spacer selected to form a ring selected from the group consisting of cycloalkyl ring having from 5 through 8 contiguous members, cycloalkenyl ring having from 5 through 8 contiguous members, and a heterocyclyl having from 5 through 8 contiguous members;
- R and R when bonded to different carbons, are optionally taken together to form a group selected from the group consisting of covalent bond, alkylene, haloalkylene, and a linear moiety spacer selected to form a ring selected from the group consisting of a cycloalkyl ring having from 5 through 8 contiguous members, a cycloalkenyl ring having from 5 through 8 contiguous members, and a heterocyclyl having from 5 through 8 contiguous members;
- R and R when bonded to different carbons, are optionally taken together to form a group selected from the group consisting of covalent bond, alkylene, haloalkylene, and a linear moiety spacer selected to form a ring selected from the group consisting of cycloalkyl ring having from 5 through 8 contiguous members, cycloalkenyl ring having from 5 through 8 contiguous members, and a heterocyclyl having from 5 through 8 contiguous members; 5 ⁇ is selected from the group consisting of NR , O, C(O), C(S), S,
- R is selected from the group consisting of hydrido, hydroxy, amino, alkyl, alkenyl, alkynyl, aryl, aralkyl, aryloxy, aralkoxy, alkoxy, alkenyloxy, alkylthio, arylthio, aralkoxyalkyl, heteroaralkoxyalkyl, aryloxyalkyl, alkoxyalkyl, alkenyloxyalkyl, alkylthioalkyl, arylthioalkyl, aralkoxyalkyl, heteroaralkoxyalkyl, alkylsulfinylalkyl, alkylsulf onylalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, haloalkyl, haloalkenyl, halocycloalkyl,
- N alkylene, haloalkylene, and a linear moiety spacer having from 2 through 7 contiguous atoms to form a ring selected from the group consisting of a cycloalkyl ring having from 3 through 8 contiguous members, a cycloalkenyl ring having from 3 through 8 contiguous members, and a heterocyclyl ring having from 3 through 8 contiguous members;
- M is selected from the group consisting of N and R -C;
- R 2 and R 1 are independently selected from the group consisting of Z 0 -
- R is optionally selected from the group consisting of amino, aminoalkyl, alkylamino, amidino, guanidino, hydroxy, hydroxyamino, alkoxy, hydroxyalkyl, alkoxyamino, thiol, alkylthio, dialkylsulfonium, trialkylphosphonium, dialkylsulfoniumalkyl, heteroarylamino, nitro, arylamino, aralkylamino, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, hydroxyhaloalkyl, cyano, and phosphono; 2 R is optionally selected from the group consisting of amidino, guanidino, dialkylsulfonium, trialkylphosphonium, dialkylsulfonium;
- R 2 and R 4a , R 2 and R 4b , R 2 and R 14 , and R 2 and R 15 are optionally independently selected to form spacer pairs wherein a spacer pair is taken together to form a linear moiety having from 2 through 5 contiguous atoms connecting the points of bonding of said spacer pair members to form a heterocyclyl ring having from 5 through 8 contiguous members with the
- R , R and R , R and R , and R and R is used at the same time;
- R is optionally independently selected to form a linear moiety having
- Z is selected from the group consisting of covalent single bond
- CR R C; vinylidene), ethynylidene (C ⁇ C; 1,2-ethynyl), 1,2-cyclopropyl, 1,2-cyclobutyl, 1,2-cyclohexyl, 1,3-cyclohexyl, 1,2-cyclopentyl, 1,3- cyclopentyl, 2,3-morpholinyl, 2,4-mo holinyl, 2,6-mo ⁇ holinyl, 3,4- morpholinyl, 3,5-morpholinyl, 1,2-piperazinyl, 1,3-piperazinyl, 2,3- piperazinyl, 2,6-piperazinyl, 1,2-piperidinyl, 13-piperidinyl, 2,3-piperidinyl, 2,4-piperidinyl, 2,6-piperidinyl, 3,4-piperidinyl, 1,2-pyrrolidinyl, 1,3- pyrrolidinyl, 2,3-pyrrolidinyl, 2,4-piperid
- R and R are independently selected from the group consisting of hydrido, hydroxyalkyl, alkyl, alkenyl, alkynyl, aryl, aralkyl, aryloxyalkyl, acyl, aroyl, aralkanoyl, heteroaroyl, aralkoxyalkyl, alkylsulfinylalkyl, alkylsulf onylalkyl, aralkyl thioalkyl, heteroaralkylthioalkyl, alkoxyalkyl, heteroaryloxyalkyl, alkenyloxyalkyl, alkylthioalkyl, arylthioalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, haloalkyl, haloalkenyl, halo
- R and R are optionally taken together to form a linear moiety spacer having from 2 through 7 contiguous atoms and forming a ring selected from the group consisting of a cycloalkyl ring having from 3 through 8 contiguous members, a cycloalkenyl ring having from 3 through 8 contiguous members, and a heterocyclyl ring having from 3 through 8 contiguous members;
- Q is formula (II):
- D , D , J , J and K are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more
- 1 2 1 2 1 1 can be O, no more than one of D , D , J , J and K can be S, one of D ,
- D , J , J and K must be a covalent bond when two of D , D , J , J and
- 1 1 2 1 2 1 K are O and S, and no more than four of D , D , J , J and K can be N,
- R , R , R , and R are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;
- Q is optionally selected from formula (III):
- 3 4 3 4 consisting of C, N, O, and S, no more than one of D , D , J , and J is O, no
- R , R , and R are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;
- Q is optionally selected from the group consisting of hydrido, alkyl, alkoxy, alkylamino, alkylthio, haloalkylthio, alkenyl, alkynyl, saturated heterocyclyl, partially saturated heterocyclyl, acyl, aroyl, heteroaroyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, cycloalkylalkenyl, haloalkyl, haloalkoxy, haloalkenyl, halocycloalkyl, halocycloalkenyl, haloalkoxy alkyl, haloalkenyloxyalkyl, halocycloalkoxyalkyl, and halocycloalkenyloxyalkyl with the proviso that Z is selected from other than a single covalent bond when Q is hydrido;
- 4a 4b K is (CR R ) n wherein n is an integer selected from 1 through 4;
- R and R are independently selected from the group consisting of halo, hydrido, hydroxy, cyano, hydroxyalkyl, alkyl, alkenyl, aryl, aralkyl, aralkoxyalkyl, aryloxyalkyl, alkoxyalkyl, heteroaryloxyalkyl, alkenyloxyalkyl, alkylthioalkyl, aralkylthioalkyl, arylthioalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkenyl, heteroaryl, heteroarylalkyl, heteroarylthioalkyl, heteroaralkylthioalkyl, cyanoalkyl, alkylsulfinylalkyl, alkylsulf onylalkyl, haloalkylsulfinyl, arylsulf ⁇ nylalkyl, arylsulfon
- 4a 4b R and R when bonded to the same carbon, are optionally taken together to form a group selected from the group consisting of oxo, thiono, and a linear spacer moiety having from 2 through 7 contiguous atoms connected to form a ring selected from the group consisting of a cycloalkyl ring having 3 through 8 contiguous members, a cycloalkenyl ring having 5 through 8 contiguous members, and a heterocyclyl ring having 5 through 8 contiguous
- E is E , when K is (CR R ) ⁇ , wherein E is selected from the group consisting of a covalent single bond, O, S, C(O), C(S), C(O)O, C(S)O, C(O)S, C(S)S, C(O)N(R ? ), (R 7 )NC(O), C(S)N(R ? ), (R 7 )NC(S),
- K is optionally selected to be (CH(R )):-T wherein j is selected from a integer from 0 through 3 and T is selected from the group consisting of single
- E is optionally E , when K is (CH(R )) -T, wherein E is selected from the group consisting of a covalent single bond, C(O), C(S), C(O)O, C(S)O, C(O)S, C(S)S, C(O)N(R 7 ), (R 7 )NC(O), C(S)N(R 7 ), (R ? )NC(S),
- K is optionally selected to be G-(CH(R )) j ⁇ wherein k is selected from an integer from 1 through 3 and G is selected from the group consisting of O,
- R is other than hydroxy, cyano, halo, amino, alkylamino, dialkylamino, and sulfhydryl when k is 1;
- E is optionally E when K is G-(CH(R )) ⁇ wherein E is selected from the group consisting of a covalent single bond, O, S, C(O), C(S),
- Y° is formula (IV):
- K is independently selected from the group
- R , and R are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;
- R and R are independently optionally taken together to form a linear moiety spacer having from 3 through 6 contiguous atoms connected to form a ring selected from the group consisting of a cycloalkenyl ring having from 5 through 8 contiguous members, a partially saturated heterocyclyl ring having from 5 through 8 contiguous members, a heteroaryl having from 5 through 6 contiguous members, and an aryl;
- R and R are independently optionally taken together to form a linear moiety spacer having from 3 through 6 contiguous atoms connected to form a ring selected from the group consisting of a cycloalkenyl ring having from 5 through 8 contiguous members, a partially saturated heterocyclyl ring having from 5 through 8 contiguous members, a heteroaryl having from 5 through 6 contiguous members, and an aryl;
- b 20 21 Q is selected from the group consisting of NR R ,
- R , and R are independently selected from the group consisting of hydrido, amino, alkyl, hydroxy, alkoxy, aminoalkylenyl, alkylamino, dialkylamino, and
- R , R , and R must be other than be hydroxy, alkoxy, alkylamino,
- R and R , R and R , and R and R are independently optionally selected to form a spacer pair wherein a spacer pair is taken together to form a linear moiety having from 4 through 7 contiguous atoms connecting the points of bonding of said spacer pair members to form a heterocyclyl ring having 5 through 8 contiguous members with the proviso that no more than
- Q is optionally selected from the group consisting of
- R , R , and R can be hydroxy, alkoxy, alkyleneamino, alkylamino, 23 24 amino, or dialkylamino when two of the group consisting of R , R , and
- Q is optionally selected from the group consisting of
- R , R , R , and R are independently selected from the group consisting of hydrido, alkyl, hydroxy, alkoxy, alkylenylamino, amino, alkylamino, dialkylamino, and hydroxyalkyl;
- R and R are optionally taken together to form a linear spacer moiety having from 4 through 7 contiguous atoms connecting the points of bonding to form a heterocyclyl ring having 5 through 8 contiguous members;
- R 30 (O)POP(O)R 3 °, Si(R 29 )R 28 , Si(R 29 )R 28 Si(R 29 )R 28 ,
- P(S)R C(R ) C(R ), DC(R )(R )D, OP(OR )R , P(O)R , P(S)R ,
- J H is independently selected from the group consisting of OR , SR and
- 27 R is selected from the group consisting of hydrido, alkyl, alkenyl, alkynyl, aralkyl, aryloxyalkyl, aralkoxyalkyl, alkylsulfinylalkyl, alkylsulf onylalkyl, aralkyl thioalkyl, heteroaralkylthioalkyl, alkoxyalkyl, heteroaryloxyalkyl, alkenyloxyalkyl, alkylthioalkyl, arylthioalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, haloalkyl, haloalkenyl, halocycloalkyl, halocycloalkenyl, halocycloalkyl, halocycloalkenyl
- R and R are independently selected from the group consisting of hydrido, hydroxy, thiol, aryloxy, amino, alkylamino, dialkylamino, hydroxyalkyl, heteroaryloxyalkyl, alkoxy, alkylthio, arylthio, alkyl, alkenyl, alkynyl, aryl, aralkyl, aryloxyalkyl, aralkoxyalkyl, alkylsulfinylalkyl, alkylsulf onylalkyl, aralkylthioalkyl, heteroaralkoxythioalkyl, alkoxyalkyl, heteroaryloxyalkyl, alkenyloxyalkyl, alkylthioalkyl, arylthioalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenyl, cyclo
- R and R are optionally taken to form a linear moiety spacer group having from 2 through 7 contiguous atoms to form a ring selected from the group consisting of a cycloalkyl ring having from 3 through 8 contiguous members, a cycloalkenyl ring having from 3 through 8 contiguous members, and a heterocyclyl ring having from 3 through 8 contiguous members;
- 26 R are independently optionally selected to form a spacer pair wherein a spacer pair is taken together from the points of bonding of selected spacer pair members to form the group L-U-V wherein L, U, and V are independently selected from the group of 1,2-disubstituted radicals consisting of a cycloalkyl radical, a cycloalkenyl radical wherein cycloalkyl and cycloalkenyl radicals are substituted with one or
- 26 R are independently optionally selected to form a spacer pair wherein a spacer pair is taken together from the points of bonding of selected spacer pair members to form the group L-U-V wherein L, U, and V are independently selected from the group of radicals consisting of 1,2-disubstituted alkylene radicals and 1,2- disubstituted alkenylene radical wherein said 1,2-substitutents are independently
- s Q is selected from the group consisting of a single covalent bond
- W is selected from 1 through 4, and W is selected from the group consisting of O,
- CR R C; vinylidene), ethynylidene (C- ⁇ C; 1,2-ethynyl), 1,2-cyclopropyl,
- R and R when bonded to different carbons, are optionally taken together to form a linear moiety spacer having from 1 through 7 contiguous atoms to form a ring selected from the group consisting of a cycloalkyl ring having from 3 through 8 contiguous members, a cycloalkenyl ring having from 3 through 8 contiguous members, and a heterocyclyl ring having from 3 through 8 contiguous members;
- R and R when bonded to different carbons, are taken together to form a linear moiety spacer having from 1 through 7 contiguous atoms to form a ring selected from the group consisting of a cycloalkyl ring having from 3 through 8 contiguous members, a cycloalkenyl ring having from 3 through 8 contiguous members, and a heterocyclyl ring having from 3 through 8 contiguous members;
- R and R when bonded to different carbons, are taken together to form a linear moiety spacer having from 1 through 7 contiguous atoms to form a ring selected from the group consisting of a cycloalkyl ring having from 3 through 8 contiguous members, a cycloalkenyl ring having from 3 through 8 contiguous members, and a heterocyclyl ring having from 3 through 8 contiguous members;
- R and R when bonded to the same carbon, are taken together to form a group selected from a group consisting of oxo, thiono, alkylene, haloalkylene, and a linear moiety spacer having from 2 through 7 contiguous atoms to form a ring selected from the group consisting of a cycloalkyl ring having from 3 through 8 contiguous members, a cycloalkenyl ring having from 3 through 8 contiguous members, and a heterocyclyl ring having from 3 through 8 contiguous members;
- Y is optionally Q -Q wherein Q is selected from the group
- W is selected from the group consisting of W is selected from the group consisting of O, S, C(O), C(S), C(O)O, C(S)O, C(O)S, C(S)S, C(O)N(R 14 ), (R 14 )NC(O), C(S)N(R 14 ), (R 14 )NC(S),
- Y° is optionally Q b -Q SSS wherein Q SSS is (CHCR 38 )),.- ⁇ , r is an
- W * ⁇ is selected from the group consisting of 1,1-cyclopropyl, 1,2-cyclopropyl, 1,1-cyclobutyl, 1,2-cyclobutyl, 1,2- cyclohexyl, 1,3-cyclohexyl, 1,4-cyclohexyl, 1,2-cyclopentyl, 1,3 -cyclopentyl, 2,3-morpholinyl, 2,4-morpholinyl, 2,5-morpholinyl, 2,6-morpholinyl, 3,4- morpholinyl, 3,5-morpholinyl, 1,2- piperazinyl, 1,3-piperazinyl, 1,4- piperazinyl, 23-piperazinyl, 2,5-piperazinyl, 2,6- piperazinyl, 1,2-piperidinyl, 1,3-piperidinyl, 1,4-piperidinyl, 2,3-piperidinyl, 2,4-piperidinyl, 2,5- piperidinyl, 2,6- piperazinyl
- Y° is optionally Q b -Q SSSr wherein Q SSSr is (CH(R 38 )) r -W 4 r is an
- W is selected from the group consisting of 1,2-cyclobutyl, 1,2-cyclohexyl, 1,3-cyclohexyl, 1,4-cyclohexyl, 1,2- cyclopentyl, 1,3-cyclopentyl, 2,3-morpholinyl, 2,4-morpholinyl, 2,5- morpholinyl, 2,6-morpholinyl, 3,4-mo holinyl, 3,5-morpholinyl, 1,2- piperazinyl, 1,3-piperazinyl, 1,4-piperazinyl, 2,3-piperazinyl, 2,5-piperazinyl, 2,6-piperazinyl, 1,2-piperidinyl, 1,3-piperidinyl, 1,4-piperidinyl, 2,3- piperidinyl, 2,4-piperidinyl, 2,5-piperidinyl, 2,6-piperidinyl, 3,4-piperidinyl, 3,5-piperidinyl, 3,
- Y° is optionally Q b -Q SSSS wherein Q SSSS is (CH(R 38 )) r -W 5 , r is an
- wW 5 ⁇ is selected from the group consisting of 1,4-indenyl, 1,5-indenyl, 1,6-indenyl, 1,7-indenyl, 2,7-indenyl, 2,6-indenyl, 2,5-indenyl, 2,4-indenyl, 3,4-indenyl, 3,5-indenyl, 3,6-indenyl, 3,7-indenyl, 2,4-benzofuranyl, 2,5-benzofuranyl, 2,6-benzofuranyl, 2,7-benzofuranyl, 3,4-benzofuranyl, 3,5-benzofuranyl, 3,6-benzofuranyl, 3,7-benzofuranyl, 2,4-benzothiophenyl, 2,5-benzothiophenyl, 2,6-benzothiophenyl, 2,7- benzothiophenyl, 3,4-benzothiophenyl, 3,5-benzothiophenyl, 3,6-benzothiophenyl,
- Y° is optionally Q b -Q ssssr wherein Q SSSSr is (CH(R 38 )) r -W 6 r is an
- W is selected from the group consisting of
- 1,4-indenyl 1,5-indenyl, 1,6-indenyl, 1,7-indenyl, 2,7-indenyl, 2,6-indenyl, 2,5-indenyl, 2,4-indenyl, 3,4-indenyl, 3,5-indenyl, 3,6-indenyl, 3,7-indenyl, 2,4-benzofuranyl, 2,5-benzofuranyl, 2,6-benzofuranyl, 2,7-benzofuranyl, 3,4-benzofuranyl, 3,5-benzofuranyl, 3,6-benzofuranyl, 3,7-benzofuranyl, 2,4-benzothiophenyl, 2,5-benzothiophenyl, 2,6-benzothiophenyl, 2,7- benzothiophenyl, 3,4-benzothiophenyl, 3,5-benzothiophenyl, 3,6-benzothiophenyl, 3,7-benzothiophenyl, 3,5-benz
- hydrido containing nitrogen member of the ring of the W other than the points of attachment is optionally substituted with one or more of the group consisting of R , R , R , and R , with the proviso that Q is bonded to
- a b J and J are independently selected from the group consisting of O and S;
- B is formula (V):
- D , D , J , J and K are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more
- K must be a covalent bond when two of D , D , J , J and K are O and S,
- R , R , R , R , and R are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;
- R , and R are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, dialkylsulfonium, trialkylphosphonium, dialkylsulfomumalkyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aryloylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, perhaloaralkyl, aralkylsulfonyl, aralkylsulfonylalkyl, aralkylsulfinyl, aralkylsulfinylalkyl, halocycloalkyl, halocycloalkenyl, cycloalkylsulfin
- R , R , R , R , R , R , and R are independently optionally b 16 19 h
- T R, 3 and , r R. 33 , T R ⁇ 33 and -, R , T R, and -. T R 3 5 , and ⁇ R >5 and ⁇ ⁇ R36 are independently optionally selected to form a spacer pair wherein a spacer pair is taken together to form a linear moiety having from 3 through 6 contiguous atoms connecting the points of bonding of said spacer pair members to form a ring selected from the group consisting of a cycloalkenyl ring having 5 through 8 contiguous members, a partially saturated heterocyclyl ring having 5 through 8 contiguous members, a heteroaryl ring having 5 through 6 contiguous members, and an aryl with the proviso that no more than one of the group
- R and R , R and R , R and R , and R and R are independently optionally selected to form a spacer pair wherein a spacer pair is taken together to form a linear moiety having from 3 through 6 contiguous atoms connecting the points of bonding of said spacer pair members to form a ring selected from the group consisting of a cycloalkenyl ring having 5 through
- B is optionally selected from the group consisting of hydrido, trialkylsilyl, C2-C8 alkyl, C3-C8 alkylenyl, C3-C8 alkenyl, C3-C8 alkynyl, C2-C8 haloalkyl, and C3-C8 haloalkenyl wherein each member of group B may be optionally substituted at any carbon up to and including 6 atoms from the point of attachment of B to A with one or more of the group consisting of
- B is optionally selected from the group consisting of C3-C15 cycloalkyl, C5-C10 cycloalkenyl, C4-C12 saturated heterocyclyl, and C4-C9 partially saturated heterocyclyl, wherein each ring carbon is optionally
- a ring carbon other than the ring carbon at the point of attachment of B to A is optionally substituted with oxo provided that no more than one ring carbon is substituted by oxo at the same time, ring carbons and a nitrogen adjacent to the carbon atom at the point of attachment are optionally
- A is selected from the group consisting of single covalent bond
- W is selected from the group consisting of O, S, C(O), C(S), C(O)S, C(S)O, C(O)N(R ? ), C(S)N(R 7 ), (R ? )NC(O), (R 7 )NC(S), S(O), S(O) 2 ,
- R and R are independently selected from the group consisting of hydrido, hydroxy, alkyl, acyl, aroyl, heteroaroyl, and alkoxyalkyl;
- R , R , R , and R are independently selected from the group consisting of hydrido, hydroxy, halo, cyano, hydroxyalkyl, alkoxy, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, haloalkyl, haloalkenyl, haloalkoxy, haloalkoxyalkyl, haloalkenyloxyalkyl, halocycloalkoxy, halocycloalkoxyalkyl, halocycloalkenyloxyalkyl, carboxy, carboxyalkyl, carboalkoxy, carboxamide, and carboxamidoalkyl; R and R can be independently selected from the group consisting of acyl, aroyl, and heteroaroyl with the proviso that acyl is selected from other than formyl;
- ⁇ is selected from the group consisting of NR , O, C(O), C(S), S,
- R is selected from the group consisting of hydrido, hydroxy, amino, alkyl, alkoxy, alkoxyalkyl, haloalkyl, acyl, aroyl, and heteroaroyl;
- R and R are independently selected from the group consisting of hydrido, hydroxy, halo, cyano, hydroxyalkyl, acyl, aroyl, heteroaroyl, acylamido, alkoxy, alkyl, alkoxyalkyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, alkyl sulfonyl, haloalkylsulfonyl, carboxy, carboxyalkyl, carboalkoxy, carboxamide, and carboxamidoalkyl;
- M is selected from the group consisting of N and R -C;
- R 2 and R 1 are independently selected from the group consisting of Z 0 - Q, hydrido, alkyl, alkenyl, and halo;
- R is optionally selected from the group consisting of amino, aminoalkyl, alkylamino, amidino, guanidino, hydroxy, hydroxyamino, alkoxy, hydroxyalkyl, alkoxyamino, thiol, alkylthio, dialkylsulfonium, trialkylphosphonium, dialkylsulfomumalkyl, heteroarylamino, nitro, arylamino, aralkylamino, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, hydroxyhaloalkyl, cyano, and phosphono;
- Z is selected from the group consisting of covalent single bond
- W (CH(R ))
- CR R C; vinylidene), ethynylidene (C ⁇ C; 1,2-ethynyl), 1,2-cyclopropyl,
- R and R are independently selected from the group consisting of amidino, hydroxyamino, hydrido, hydroxy, amino, halo, cyano, aryloxy, hydroxyalkyl, acyl, aroyl, heteroaroyl, heteroaryloxyalkyl, alkoxy, alkyl, aryl, aralkyl, aryloxyalkyl, aralkoxyalkylalkoxy, alkoxyalkyl, heteroaryloxyalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, haloalkyl, haloalkenyl, halocycloalkyl, halocycloalkenyl, haloalkoxy, haloalkoxyalkyl, haloalkenyloxyalkyl, halocycloalkoxyalkyl, haloalken
- D , D , J , J and K are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more
- K must be a covalent bond when two of D , D , J , J and K are O and S,
- R , R , R , R , and R are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;
- 3 4 3 4 consisting of C, N, O, and S, no more than one of D , D , J , and J is O, no 3 4 3 4 1 2 more than one of D , D , J , and J is S, and no more than three of D , D ,
- R , R , and R are N with the proviso that R , R , R , and R are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;
- Q is optionally selected from the group consisting of hydrido, alkyl, alkoxy, alkylamino, alkylthio, haloalkylthio, alkenyl, alkynyl, saturated heterocyclyl, partially saturated heterocyclyl, acyl, aroyl, heteroaroyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, cycloalkylalkenyl, haloalkyl , haloalkoxy, haloalkenyl , halocycloalkyl , halocycloalkenyl , haloalkoxyalkyl, haloalkenyloxyalkyl, halocycloalkoxyalkyl, haloalkenyloxyalkyl, halocycloalkoxyalkyl, and halocycloalkenyloxyalkyl with the proviso that
- 4a 4b K is (CR R ) n wherein n is an integer selected from 1 through 2;
- R and R are independently selected from the group consisting of halo, hydrido, hydroxy, cyano, hydroxyalkyl, alkyl, alkenyl, alkoxyalkyl, aralkyl, heteroaralkyl, alkylthioalkyl, haloalkyl, haloalkenyl, and cyanoalkyl; o 1 4a 4b 1
- E is E , when K is (CR R ) n , wherein E is selected from the group consisting of a covalent single bond, O, S, C(O), C(S), C(O)O, C(S)O, C(O)S, C(S)S, C(O)N(R ? ), (R ? )NC(O), C(S)N(R 7 ), (R 7 )NC(S),
- 4a 4b ethynylidene (C- ⁇ C; 1,2-ethynyl), and C CR R ; 14 K is optionally (CH(R )):-T wherein j is selected from a integer from
- T is selected from the group consisting of single covalent
- K is optionally G-(CH(R )) j - wherein k is selected from an integer from 1 through 2 and G is selected from the group consisting of O, S, and
- R is other than hydroxy, cyano, halo, amino, alkylamino, dialkylamino, and sulfhydryl when k is 1;
- E is optionally E when K is G-(CH(R )) j ⁇ , wherein E is selected from the group consisting of a covalent single bond, O, S, C(O), C(S),
- D , D , J , and J are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more
- K is independently selected from the group
- D , D , J , and J are N when K is carbon with the provisos that R , R ,
- R , and R are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;
- R and R are optionally independently taken together to form a linear moiety spacer having from 3 through 6 contiguous atoms connected to form a ring selected from the group consisting of a cycloalkenyl ring having from 5 through 8 contiguous members, a partially saturated heterocyclyl ring having from 5 through 8 contiguous members, a heteroaryl having from 5 through 6 contiguous members, and an aryl; b 20 21
- Q is selected from the group consisting of NR R ,
- NR R R oxy, alkyl, aminoalkylenyl, alkylamino, dialkylamino, be be 20 dialkylsulfomumalkyl, acylamino and Q , wherein Q is hydrido and R ,
- R , and R are independently selected from the group consisting of hydrido, amino, alkyl, hydroxy, alkoxy, aminoalkylenyl, alkylamino, dialkylamino, and
- R , R , and R must be other than be hydroxy, alkoxy, alkylamino,
- R and R , and R and R are independently optionally selected to form a spacer pair wherein a spacer pair is taken together to form a linear moiety having from 4 through 7 contiguous atoms connecting the points of bonding of said spacer pair members to form a heterocyclyl ring having 5 through 8 contiguous members with the proviso that no more than
- R and R is used at the same time
- Q is optionally selected from the group consisting of
- R 23 24 26 of R , R , and R is hydroxy, alkoxy, alkylamino, amino, and
- Q is optionally selected from the group consisting of
- R , R , R , and R are independently selected from the group consisting of hydrido, alkyl, hydroxy, alkoxy, aminoalkylenyl, alkylamino, dialkylamino, amino, and hydroxyalkyl;
- R and R are optionally taken together to form a linear spacer moiety having from 4 through 7 contiguous atoms connecting the points of bonding to form a heterocyclyl ring having 5 through 8 contiguous members;
- Q is selected from the group consisting of a single covalent bond
- az is an integer selected from 0 through 1
- b is an integer selected from 1 through 4
- W is selected from the group consisting of O, S, C(O), C(S), C(O)O, C(S)O, C(O)S, C(S)S, C(O)N(R 14 ),
- W is selected from the group
- W ⁇ is selected from the group
- 1,2-ethynyl 1,2-cyclopropyl, 1,2-cyclobutyl, 1,2-cyclohexyl, 1,3- cyclohexyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 2,3-mo ⁇ holinyl, 2,4- mo ⁇ holinyl, 2,6-mo ⁇ holinyl, 3,4-mo ⁇ holinyl, 3,5-mo ⁇ holinyl, 1,2- piperazinyl, 1,3-piperazinyl, 2,3-piperazinyl, 2,6-piperazinyl, 1,2-piperidinyl, 1,3-piperidinyl, 2,3-piperidinyl, 2,4-piperidinyl, 2,6-piperidinyl, 3,4- piperidinyl, 1,2-pyrrolidinyl, 1,3-pyrrolidinyl, 2,3-pyrrolidinyl, 2,4- pyrrolidinyl, 2,5-pyrrolidinyl, 3,4
- R and R are selected from other than halo and cyano when
- Y is optionally Q -Q wherein Q is selected from the group
- W is selected from the group consisting of W is selected from the group consisting of O, S, C(O), C(S), C(O)O, C(S)O, C(O)S, C(S)S, C(O)N(R 14 ), (R M )NC(O), C(S)N(R 14 ), (R 14 )NC(S),
- e and h are integers independently selected from 0 through 2 and w 2
- R 38 ) f , (CH(R 14 )) C , and (CH(R 14 )) e are bonded to E°;
- Y° is optiionally Q b -Q SSS wherein Q SSS is (C ⁇ R 38 )),. ⁇ , r is an
- W ⁇ ⁇ is selected from the group consisting of
- Y° is optionally Q b -Q SSSr wherein Q SSSr is (CH(R 38 )) r -W 4 r is an
- W is selected from the group consisting of
- W is selected from the group consisting of 1,4-indenyl, 1,5-indenyl, 1,6-indenyl, 1,7-indenyl, 2,7-indenyl, 2,6-indenyl, 2,5-indenyl, 2,4-indenyl, 3,4-indenyl, 3,5-indenyl, 3,6-indenyl, 3,7-indenyl, 2,4-benzof uranyl, 2,5-benzof uranyl, 2,6-benzof uranyl, 2,7-benzofuranyl, 3, 4-benzof uranyl, 3, 5-benzof uranyl, 3,6-benzofuranyl, 3,7-benzofuranyl, 2,4-benzothiophenyl, 2,5-benzothiophenyl, 2,6-benzothiophenyl, 2,7- benzothiophenyl, 3,4-benzothiophenyl, 3,5-benzothiophenyl, 3,6- benzothiophenyl,
- Y is optionally Q -Q wherein Q is (CH(R )) r -W , r is an
- W is selected from the group consisting of 1,4-indenyl, 1,5-indenyl, 1,6-indenyl, 1,7-indenyl, 2,7-indenyl, 2,6-indenyl, 2,5-indenyl, 2,4-indenyl, 3,4-indenyl, 3,5-indenyl, 3,6-indenyl, 3,7-indenyl, 2,4-benzof uranyl, 2,5-benzof uranyl, 2,6-benzofuranyl, 2,7-benzof uranyl, 3,4-benzofuranyl, 3,5-benzofuranyl, 3,6-benzofuranyl, 3,7-benzofuranyl, 2,4-benzothiophenyl, 2,5-benzothiophenyl, 2,6-benzothiophenyl, 2,7- benzothiophenyl, 3,4-benzothiophenyl, 3,5-benzothiophenyl, 3,6- benzothiophenyl, 3,
- a b J and J are independently selected from the group consisting of O and S;
- D , D , J , J and K are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more
- K must be a covalent bond when two of D , D , J , J and K are O and S,
- R , and R are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, dialkylsulfonium, trialkylphosphonium, dialkylsulfomumalkyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aryloylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, perhaloaralkyl, aralkylsulfonyl, aralkylsulf onylalkyl, aralkylsulfmyl, aralkylsulfinylalkyl, halocycloalkyl, halocycloalkenyl, cycloalkylsulfiny
- R , R , R , R , and R are independently optionally
- B is optionally selected from the group consisting of hydrido, trialkylsilyl, C2-C8 alkyl, C3-C8 alkylenyl, C3-C8 alkenyl, C3-C8 alkynyl, C2-C8 haloalkyl, and C3-C8 haloalkenyl wherein each member of group B is optionally substituted at any carbon up to and including 6 atoms from the point
- B is optionally selected from the group consisting of C3-C12 cycloalkyl, C5-C10 cycloalkenyl, and C4-C9 saturated heterocyclyl, wherein
- each ring carbon is optionally substituted with R
- a ring carbon other than the ring carbon at the point of attachment of B to A is optionally substituted with oxo provided that no more than one ring carbon is substituted by oxo at the same time
- R 10 is optionally substituted with R , a ⁇ ng carbon or nitrogen adjacent to the
- R 12 33 to the R position is optionally substituted with R , and a ring carbon or
- R positions is optionally substituted with R ;
- A is selected from the group consisting of single covalent bond
- W 7 7 selected from 0 through 1
- pa is an integer selected from 0 through 6
- W 7 7 is selected from the group consisting of O, S, C(O), C(0)N(R ), C(S)N(R ),
- R and R are independently selected from the group consisting of hydrido, hydroxy, alkyl, and alkoxyalkyl;
- R , R , R , and R are independently selected from the group consisting of hydrido, hydroxy, halo, alkyl, alkoxyalkyl, haloalkyl, haloalkoxy, and haloalkoxyalkyl;
- R and R can be independently selected from the group consisting of aroyl and heteroaroyl
- ⁇ is selected from the group consisting of NR , C(O), and S(O) 2 ;
- R is selected from the group consisting of hydrido, alkyl, alkenyl, cyano, halo, haloalkyl, haloalkoxy, haloalkylthio, amino, aminoalkyl, alkylamino, amidino, guanidino, hydroxy, hydroxyamino, alkoxy, hydroxyalkyl, alkoxyamino, thiol, alkylthio, and phosphono;
- Z is selected from the group consisting of covalent single bond
- h are integers independently selected from 0 through 2 and W ⁇ is selected
- R and R are independently selected from the group consisting of amidino, hydroxyamino, hydrido, hydroxy, amino, and alkyl:
- D , D , J , J and K are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more
- R , R , R , R , and R are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;
- 4a 4b K is (CR R ) n wherein n is an integer selected from 1 through 2;
- D , D , J , and J are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more than one is a covalent bond, K is C, no more than one of D , D , J , and J
- Q is selected from the group consisting of NR R ,
- R , and R are independently selected from the group consisting of hydrido, alkyl, hydroxy, amino, aminoalkylenyl, dialkylamino, alkylamino, and
- R 23 24 26 of R , R , and R is hydroxy, alkylamino, amino, or dialkylamino when
- Q is selected from the group consisting of a single covalent bond
- W is selected from the group
- W ⁇ is selected from the group
- R and R are selected from other than halo and cyano when
- 14 is selected from the group consisting of O, S, C(O), C(O)N(R ), 14 15 14 14 15 14 14
- W ⁇ is selected from the group consisting of
- Y° is optionally Q b -Q SSS wherein Q SSS is (C ⁇ R 38 )) ⁇ , r i s an
- W W ⁇ iss selected from the group consisting of 1,1-cyclopropyl, 1,2-cyclopropyl, 1,1-cyclobutyl, 1,2-cyclobutyl, 1,2- cyclohexyl, 1,3-cyclohexyl, 1,4-cyclohexyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 2,3-mo ⁇ holinyl, 2,4-mo ⁇ holinyl, 2,5-mo ⁇ holinyl, 2,6-mo ⁇ holinyl, 3,4- mo ⁇ holinyl, 3,5-mo ⁇ holinyl, 1,2-piperazinyl, 1,3-piperazinyl, 1,4- piperazinyl, 2,3-piperazinyl, 2,5-piperazinyl, 2,6-piperazinyl, 1,2-piperidinyl, 1,3-piperidinyl, 1,4-piperidinyl, 2,3-piperidinyl, 2,3-piperidinyl,
- Y° is optionally Q b -Q SSSr wherein Q SSSr is (CH(R 38 )) r -W 4 , r is an
- W is selected from the group consisting of 1,2-cyclobutyl, 1,2-cyclohexyl, 1,3-cyclohexyl, 1,4-cyclohexyl, 1,2- cyclopentyl, 1,3-cyclopentyl, 2,3-mo ⁇ holinyl, 2,4-mo ⁇ holinyl, 2,5- mo ⁇ holinyl, 2,6-mo ⁇ holinyl, 3,4-mo ⁇ holinyl, 3,5-mo ⁇ holinyl, 1,2- piperazinyl, 1,3 -piperazinyl, 1,4-piperazinyl, 2,3-piperazinyl, 2,5- piperazinyl, 2,6-piperazinyl, 1,2-piperidinyl, 1,3-piperidinyl, 1,4-piperidinyl, 2,3- piperidinyl, 2,4-piperidinyl, 2,5-piperidinyl, 2,6-piperidinyl, 3,4-pipe
- Y° is optionally Q b -Q SSSS wherein Q SSSS is (CH(R 38 )) r -W 5 , r i s an
- W ⁇ ⁇ is selected from the group consisting of 1,4-indenyl, 1,5-indenyl, 1,6-indenyl, 1,7-indenyl, 2,7-indenyl, 2,6-indenyl, 2,5-indenyl, 2,4-indenyl, 3,4-indenyl, 3,5-indenyl, 3,6-indenyl, 3,7-indenyl, 2,4-benzof uranyl, 2,5-benzofuranyl, 2,6-benzof uranyl, 2,7- benzof uranyl, 3, 4-benzof uranyl, 3, 5-benzof uranyl, 3, 6- benzof uranyl, 3, 7- benzof uranyl, 2,4-benzothiophenyl, 2,5-benzothiophenyl, 2,6-benzothiophenyl, 2,7- benzothiophenyl, 3,4-benzothiophenyl, 3,5-benzothiophenyl,
- W is selected from the group consisting of
- 1,4-indenyl 1,5-indenyl, 1,6-indenyl, 1,7-indenyl, 2,7-indenyl, 2,6-indenyl, 2,5-indenyl, 2,4-indenyl, 3,4-indenyl, 3,5-indenyl, 3,6-indenyl, 3,7-indenyl, 2,4-benzofuranyl, 2,5-benzof uranyl, 2,6-benzofuranyl, 2,7- benzof uranyl, 3, 4-benzof uranyl, 3, 5-benzof uranyl, 3,6-benzofuranyl, 3, 7- benzof uranyl, 2,4-benzothiophenyl, 2,5-benzothiophenyl, 2,6-benzothiophenyl, 2,7- benzothiophenyl, 3,4-benzothiophenyl, 3,5-benzothiophenyl, 3,6- benzothiophenyl, 3,7-benzothiophen
- D , D , J , J and K are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more
- K must be a covalent bond when two of D , D , J , J and K are O and S,
- T R, 9 «R 10 , n RH , TR, 12 , R r, 13 , R T, 32 , TR. 33 , TR, 34 , ⁇ R , and , rR, 36 are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkylenedioxy, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, haloalkoxylalkyl, hydroxy, amino, alkoxyamino, nitro, lower alkylamino, alkylthio, alkylthioalkyl, alkylsulfinyl, alkylsulfonyl, alkylsulf onylalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, alkylsul
- R , R , R , R , R , and R are independently optionally
- B is optionally selected from the group consisting of hydrido, trialkylsilyl, C2-C8 alkyl, C3-C8 alkylenyl, C3-C8 alkenyl, C3-C8 alkynyl, and C2-C8 haloalkyl, wherein each member of group B is optionally substituted at any carbon up to and including 6 atoms from the point of
- B is optionally selected from the group consisting of C3-C12 cycloalkyl and C4-C9 saturated heterocyclyl, wherein each ring carbon may be
- a ring carbon other than the ring carbon at the point of attachment of B to A is optionally substituted with oxo provided that no more than one ring carbon is substituted by oxo at the same time, ring carbons and a nitrogen adjacent to the carbon atom at the point of attachment
- 9 13 may be optionally substituted with R or R , a ring carbon or nitrogen
- R 10 13 optionally substituted with R , a ring carbon or nitrogen adjacent to the R position and two atoms from the point of attachment is optionally substituted
- R 10 11 and adjacent to the R position is optionally substituted with R , a ring carbon or nitrogen three atoms from the point of attachment and adjacent to the
- R position is optionally substituted with R , and a ring carbon or nitrogen
- A is selected from the group consisting of single covalent bond
- 7 7 is selected from the group consisting of O, S, C(O), (R )NC(O), (R )NC(S), 7 and N(R ) with the proviso that no more than one of the group consisting of rr and pa is 0 at the same time;
- R is selected from the group consisting of hydrido, hydroxy, and alkyl
- R is selected from the group consisting of hydrido, hydroxy, halo, alkyl, and haloalkyl;
- ⁇ is selected from the group consisting of NH and NOH;
- M is selected from the group consisting of N and R -C;
- R is selected from the group consisting of hydrido, alkyl, alkenyl, cyano, halo, haloalkyl, haloalkoxy, haloalkylthio, amino, aminoalkyl, alkylamino, amidino, hydroxy, hydroxyamino, alkoxy, hydroxyalkyl, alkoxyamino, thiol, and alkylthio;
- R 2 is Z°-Q
- Z is selected from the group consisting of covalent single bond
- W ⁇ is selected from
- CR CR , 1,2-cyclopropyl, 1,2-cyclobutyl, 1,2- cyclohexyl, 1,3-cyclohexyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 2,3- mo ⁇ holinyl, 2,4-mo ⁇ holinyl, 2,6-mo ⁇ holinyl, 3,4-mo ⁇ holinyl, 3,5- mo ⁇ holinyl, 1,2-piperazinyl, 1,3-piperazinyl, 2,3-piperazinyl, 2,6- piperazinyl, 1,2-piperidinyl, 1,3-piperidinyl, 2,3-piperidinyl, 2,4-piperidinyl, 2,6-piperidinyl, 3, 4- piperidinyl, 1,2-pyrrolidinyl, 1,3-pyrrolidinyl, 2,3- pyrrolidinyl, 2,4-pyrrolidinyl, 2,5-pyrrolidinyl,
- R and R are independently selected from the group consisting of amidino, hydroxyamino, hydrido, hydroxy, amino, and alkyl;
- Q is selected from the group consisting of hydrido, with the proviso that Z is other than a covalent single bond, and the formula (II):
- D , D , J , J and K are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more
- R , R , R , R , and R are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;
- 4a 4b K is (CR R ) n wherein n is an integer selected from 1 through 2;
- R and R are independently selected from the group consisting of halo, hydrido, hydroxyalkyl, alkyl, alkoxyalkyl, alkylthioalkyl, and haloalkyl; E is E , when K is (CR II ) n , wherein E is selected from the
- D , D , J , and J are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more than one is a covalent bond, K is C, no more than one of D , D , J , and J
- R , and R are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;
- R 23 24 more than one of R and R is hydroxy, amino, alkylamino, or dialkylamino at the same time;
- R , R , R , R , R , and R are independently selected from the group consisting of hydrido, alkyl, hydroxy, aminoalkylenyl, amino, dialkylamino, alkylamino, and hydroxyalkyl; s Q is selected from the group consisting of a single covalent bond,
- W is selected from 1 through 3 and W is selected from the group consisting of
- R is selected from the group consisting of hydrido, halo, alkyl, and haloalkyl;
- R is optionally selected from the group consisting of aroyl and heteroaroyl; Y° is optionally Q b -Q SS wherein Q SS is (CH(R 14 )) e -W 2 -(CH(R 15 )) h ,
- e and h are integers independently selected from 1 through 2 and w 2
- Y is optionally selected from the group consisting of Q -Q and Q -
- Q SSSS1* wherein Q SSSS is (CH R ⁇ -W 5 and Q SSSsr is (CH(R 38 )) r -W 6 , r is an
- W and W are independently selected from the group consisting of 1,4-indenyl, 1,5-indenyl, 1,6-indenyl, 1,7- indenyl, 2,7-indenyl, 2,6-indenyl, 2,5-indenyl, 2,4-indenyl, 3,4-indenyl, 3,5- indenyl, 3,6-indenyl, 3,7-indenyl, 2,4-benzofuranyl, 2,5 ⁇ benzofuranyl, 2,6- benzofuranyl, 2,7-benzof uranyl, 3, 4-benzof uranyl, 3, 5-benzof uranyl, 3,6- benzofuranyl, 3,7-benzofuranyl, 2,4-benzothiophenyl, 2,5-benzothiophenyl, 2,6-benzothiophenyl, 2,7-benzothio ⁇ henyl, 3,4-benzothiophenyl, 3,5- benzothiophenyl, 3,6-
- W is optionally substituted with one or more of the group consisting of
- J and J are each O;
- B is selected from the group consisting of aryl and heteroaryl wherein a carbon adjacent to the carbon at the point of attachment is optionally substituted
- R , R , R , R , and R are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkylenedioxy, haloalkylthio, alkanoyloxy, alkoxy, hydroxy, amino, alkoxyamino, alkanoyl, haloalkanoyl, nitro, lower alkylamino, alkylthio, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, alkylsulf onamido, amidosulfonyl, monoalkyl amidosulfonyl, dialkyl amidosulfonyl, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, haloalkoxy, hydroxyalkyl, alkyl enyl amino, carb
- B is optionally selected from the group consisting of C3-C12 cycloalkyl and C4-C9 saturated heterocyclyl, wherein each ring carbon is
- a ring carbon other than the ring carbon at the point of attachment of B to A is optionally substituted with oxo provided that no more than one ring carbon is substituted by oxo at the same time, ring carbons and a nitrogen adjacent to the carbon atom at the point of
- R 10 13 optionally substituted with R , a ring carbon or nitrogen adjacent to the R position and two atoms from the point of attachment is optionally substituted
- R 10 11 and adjacent to the R position is optionally substituted with R , a ring carbon or nitrogen three atoms from the point of attachment and adjacent to the
- R position is optionally substituted with R , and a ring carbon or nitrogen
- R , R , R , R , and R are independently selected from the group consisting of hydrido, acetamido, haloacetamido, alkoxyamino, alkanoyl, haloalkanoyl, amidino, guanidino, alkyl enedi oxy, haloalkylthio, alkoxy, hydroxy, amino, lower alkylamino, alkylthio, alkylsulfinyl, alkylsulf onyl, alkylsulf onamido, amidosulfonyl, monoalkyl amidosulfonyl, dialkyl amidosulfonyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, carboalkoxy, carboxyalkyl, carboxy, carboxamido, and cyano;
- A is selected from the group consisting of single covalent bond and
- W is selected from the group
- R is selected from the group consisting of hydrido, hydroxy and alkyl
- R is selected from the group consisting of hydrido, hydroxy, halo, alkyl, and haloalkyl; ⁇ is NH;
- M is selected from the group consisting of N and R -C;
- R is selected from the group consisting of hydrido, alkyl, cyano, halo, haloalkyl, haloalkoxy, amino, aminoalkyl, alkylamino, amidino, hydroxy, hydroxyamino, alkoxy, hydroxyalkyl, alkoxyamino, thiol, and alkylthio;
- R 2 is Z°-Q
- Z is selected from the group consisting of covalent single bond and
- W ⁇ is selected from the group consisting of
- CR CR , 1,2-cyclopropyl, 1,2-cyclobutyl, 1,2-cyclohexyl, 1,3- cyclohexyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 2,3-mo ⁇ holinyl, 2,4- mo ⁇ holinyl, 2,6-mo ⁇ holinyl, 3,4-mo ⁇ holinyl, 3,5-mo ⁇ holinyl, 1,2- piperazinyl, 1,3-piperazinyl, 2,3-piperazinyl, 2,6-piperazinyl, 1,2-piperidinyl, 13-piperidinyl, 2,3-piperidinyl, 2,4- piperidinyl, 2,6-piperidinyl, 3,4- piperidinyl, 1,2-pyrrolidinyl, 1,3-pyrrolidinyl, 23-pyrrolidinyl, 2,4- pyrrolidinyl, 2,5-pyrrolidinyl, 3,4-pyrrol
- R and R are independently selected from the group consisting of hydrido, hydroxy, and amino;
- Q is selected from the group consisting of hydrido, with the proviso that Z is other than a covalent single bond, aryl, and heteroaryl, wherein a carbon adjacent to the carbon at the point of attachment is optionally substituted
- K is CHR wherein R is selected from the group consisting of hydrido, hydroxyalkyl, alkyl, alkoxyalkyl, alkylthioalkyl, and haloalkyl; E is selected from the group consisting of a covalent single bond, C(O)N(H), (H)NC(O), (R ? )NS(O) 2 , and S(O) 2 N(R 7 );
- D , D , J , and J are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more
- K is C, no more than one of D , D , J , and J
- 5 6 5 6 5 6 5 6 5 6 5 6 is O, no more than one of D , D , J , and J is S, one of D , D , J , and J
- R , and R are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;
- R , R , R , and R are independently selected from the group consisting of hydrido, amidino, guanidino, carboxy, haloalkylthio, alkoxy, hydroxy, amino, alkoxyamino, lower alkylamino, alkylthio, alkylsulfinyl, alkyl sulfonyl, alkanoyl, haloalkanoyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, and cyano;
- R and R are optionally Q with the proviso that no more than one
- Q is selected from the group consisting of NR R , Q wherein Q is
- R , R , R , R , R , and R are independently selected from the group consisting of hydrido, alkyl, hydroxy, amino, alkylamino and dialkylamino;
- Q is selected from the group consisting of a single covalent bond,
- W is selected from 1 through 3 and W is selected from the group consisting of
- R is selected from the group consisting of hydrido, halo, alkyl, and haloalkyl;
- R and R are independently selected from the group consisting of hydrido, alkyl, and haloalkyl;
- 38 R is optionally selected from the group consisting of aroyl and heteroaroyl; ss ss . ,. 14. 15.
- Y° is optionally Q " -Q " wherein Q M is (CH(R ' " )) e - -wW 2"* --(CH(R )) h ,
- e and h are integers independently selected from 1 through 2 and w 2
- B is selected from the group consisting of aryl and heteroaryl wherein a carbon adjacent to the carbon at the point of attachment is optionally substituted 32 by R , the other carbon adjacent to the carbon at the point of attachment is
- R , R , R , R , and R are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkoxy, hydroxy, amino, alkoxyamino, lower alkylamino, alkylthio, amidosulfonyl, monoalkyl amidosulfonyl, dialkyl amidosulfonyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, carboalkoxy, carboxy, carboxamido, cyano, and Q ;
- A is selected from the group consisting of single covalent bond and
- W is selected from the group
- R is selected from the group consisting of hydrido, hydroxy and alkyl
- R is selected from the group consisting of hydrido, halo, alkyl, and haloalkyl; ⁇ is NH;
- M is selected from the group consisting of N and R -C;
- R is selected from the group consisting of hydrido, hydroxy, hydroxyamino, amidino, amino, cyano, hydroxyalkyl, alkoxy, alkyl, alkylamino, aminoalkyl, alkylthio, alkoxyamino, haloalkyl, haloalkoxy, and halo;
- R 2 is Z°-Q;
- Z is selected from the group consisting of a covalent single bond, O,
- Q is selected from the group consisting of aryl and heteroaryl wherein a carbon adjacent to the carbon at the point of attachment is optionally substituted
- R , R , and R are independently selected from the group consisting of hydrido, hydroxy, amino, amidino, guanidino, lower alkylamino, alkylthio, alkylsulfonamido, alkylsulfinyl, alkylsulf onyl, amidosulfonyl, monoalkyl amidosulfonyl, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxyalkyl, carboxy, carboxamido, and cyano;
- R and R are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkyl, alkoxy, hydroxy, amino, alkoxyamino, lower alkylamino, alkylsulfonamido, amidosulfonyl, monoalkyl amidosulfonyl, dialkyl amidosulfonyl, hydroxyalkyl, aminoalkyl, carboalkoxy, carboxy, carboxyalkyl, amidocarbonyl, halo, haloalkyl, and cyano;
- K is CH 2 ;
- E° is C(O)N(H); Y° is formula (IV):
- D , D , J , and J are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more than one is a covalent bond, K is C, no more than one of D , D , J , and J
- 5 6 5 6 is optionally O, no more than one of D , D , J , and J is optionally S, one of
- D , D , J , and J must be a covalent bond when two of D , D , J , and J
- R , R , R , and R are independently selected from the group consisting of hydrido, amidino, guanidino, carboxy, haloalkylthio, alkoxy, hydroxy, amino, lower alkylamino, alkylthio, alkylsulfinyl, alkylsulf onyl, alkanoyl, haloalkanoyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, and cyano;
- R and R are optionally Q with the proviso that no more than one of
- R and R is Q at the same time and that Q is Q ;
- 21 23 24 and R is hydroxy at the same time and that no more than one of R and R is hydroxy at the same time;
- R , R , R , R , and R are independently selected from the group consisting of hydrido, alkyl, and hydroxy; s Q is selected from the group consisting of a single covalent bond,
- a b J and J are each O;
- B is optionally selected from the group consisting of hydrido, C2-C8 alkyl, C3-C8 alkenyl, C3-C8 alkynyl, and C2-C8 haloalkyl, wherein each member of group B is optionally substituted at any carbon up to and including 6 atoms from the point of attachment of B to A with one or more of the group r 32 33 34 35 , 36 consisting of R , R , R , R , and R ;
- R , R , R , R , and R are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkoxy, hydroxy, amino, alkoxyamino, lower alkylamino, alkylthio, amidosulfonyl, monoalkyl amidosulfonyl, dialkyl amidosulfonyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, carboalkoxy, carboxy, carboxamido, cyano, and Q ;
- A is selected from the group consisting of single covalent bond and
- W is selected from the group
- R is selected from the group consisting of hydrido, hydroxy and alkyl
- R is selected from the group consisting of hydrido, halo, alkyl, and haloalkyl;
- R is selected from the group consisting of hydrido, hydroxy, hydroxyamino, amidino, amino, cyano, hydroxyalkyl, alkoxy, alkyl, alkylamino, aminoalkyl, alkylthio, alkoxyamino, haloalkyl, haloalkoxy, and halo;
- R 2 is Z°-Q
- Z is selected from the group consisting of a covalent single bond, O, S, NH, and CH 2 ;
- Q is selected from the group consisting of aryl and heteroaryl wherein a carbon adjacent to the carbon at the point of attachment is optionally substituted
- R , R , and R are independently selected from the group consisting of hydrido, hydroxy, amino, amidino, guanidino, lower alkylamino, alkylthio, alkylsulfonamido, alkylsulfinyl, alkylsulf onyl, amidosulfonyl, monoalkyl amidosulfonyl, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxyalkyl, carboxy, carboxamido, and cyano;
- R and R are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkyl, alkoxy, hydroxy, amino, alkoxyamino, lower alkylamino, alkylsulfonamido, amidosulfonyl, monoalkyl amidosulfonyl, dialkyl amidosulfonyl, hydroxyalkyl, alkylenylamino, carboalkoxy, carboxy, carboxyalkyl, amidocarbonyl, halo, haloalkyl, and cyano; K is CH 2 ;
- E° is C(O)N(H); Y° is formula (IV):
- K is C, no more than one of D , D , J , and J
- 5 6 5 6 5 6 5 6 5 6 5 6 is O, no more than one of D , D , J , and J is S, one of D , D , J , and J
- R , and R are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;
- R , R , R , and R are independently selected from the group consisting of hydrido, amidino, guanidino, carboxy, haloalkylthio, alkoxy, hydroxy, amino, lower alkylamino, alkylthio, alkylsulfinyl, alkylsulf onyl, alkanoyl, haloalkanoyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkylenylamino, and cyano;
- R and R are optionally Q with the proviso that no more than one
- R and R is Q at the same time and that Q is Q ;
- Q is selected from the group consisting of NR R , Q wherein
- R , R , R , R , R , and R are independently selected from the group consisting of hydrido, alkyl, and hydroxy; Q is selected from the group consisting of a single covalent bond,
- J and J are each O;
- B is optionally selected from the group consisting of C3-C7 cycloalkyl and C4-C6 saturated heterocyclyl, wherein each ring carbon is optionally
- a ring carbon other than the ring carbon at the point of attachment of B to A is optionally substituted with oxo provided that no more than one ring carbon is substituted by oxo at the same time, ring carbons and a nitrogen adjacent to the carbon atom at the point of attachment are optionally
- R 33 optionally substituted with R , and a ring carbon or nitrogen four atoms from
- R , R , and R are independently selected from the group consisting of hydrido, hydroxy, amino, amidino, guanidino, lower alkylamino, alkylthio, alkylsulfonamido, alkylsulfinyl, alkylsulf onyl, amidosulfonyl, monoalkyl amidosulfonyl, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxyalkyl, carboxy, carboxamido, and cyano;
- R and R are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkyl, alkoxy, hydroxy, amino, alkoxyamino, lower alkylamino, alkylsulfonamido, amidosulfonyl, monoalkyl amidosulfonyl, dialkyl amidosulfonyl, hydroxyalkyl, alkylenylamino, carboalkoxy, carboxy, carboxyalkyl, amidocarbonyl, halo, haloalkyl, and cyano;
- R and R are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkoxy. hydroxy, amino, alkoxyamino, lower alkylamino, alkylthio, amidosulfonyl, monoalkyl amidosulfonyl, dialkyl amidosulfonyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, carboalkoxy, carboxy, carboxamido, cyano, and Q ;
- A is selected from the group consisting of single covalent bond and
- W is selected from the group
- R is selected from the group consisting of hydrido, hydroxy and alkyl
- R is selected from the group consisting of hydrido, halo, alkyl, and haloalkyl;
- R is selected from the group consisting of hydrido, hydroxy, hydroxyamino, amidino, amino, cyano, hydroxyalkyl, alkoxy, alkyl, alkylamino, aminoalkyl, alkylthio, alkoxyamino, haloalkyl, haloalkoxy, and halo;
- R 2 is Z°-Q
- Z is selected from the group consisting of a covalent single bond, O, S, NH, and CH 2 ;
- Q is selected from the group consisting of aryl and heteroaryl wherein a carbon adjacent to the carbon at the point of attachment is optionally substituted
- D , D , J , and J are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more than one is a covalent bond
- K is C, no more than one of D , D , J , and J 5 6 5 6 .
- . 5 6 5 6 is O, no more than one of D , D , J , and J is S, one of D , D , J , and J
- R , and R are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;
- R , R , R , and R are independently selected from the group consisting of hydrido, amidino, guanidino, carboxy, haloalkylthio, alkoxy, hydroxy, amino, lower alkylamino, alkylthio, alkylsulfinyl, alkylsulf onyl, alkanoyl, haloalkanoyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkylenylamino, and cyano;
- R and R are optionally Q with the proviso that no more than one of
- R and R is Q at the same time and that Q is Q ;
- 21 23 24 and R is hydroxy at the same time and that no more than one of R and R is hydroxy at the same time;
- R , R , R , R , and R are independently selected from the group consisting of hydrido, alkyl, and hydroxy; g Q is selected from the group consisting of a single covalent bond,
- J and J are each O;
- B is selected from the group consisting of aryl and heteroaryl wherein a carbon adjacent to the carbon at the point of attachment is optionally substituted 32 by R , the other carbon adjacent to the carbon at the point of attachment is
- R , R , R , and R are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkoxy, hydroxy, amino, alkoxyamino, lower alkylamino, alkylthio, amidosulfonyl, monoalkyl amidosulfonyl, dialkyl amidosulfonyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, carboalkoxy, carboxy, carboxamido, cyano, and Q ;
- A is selected from the group consisting of single covalent bond and
- W is N(R );
- R is selected from the group consisting of hydrido and alkyl
- R is selected from the group consisting of hydrido, halo, alkyl, and haloalkyl;
- R is selected from the group consisting of hydrido, hydroxy, hydroxyamino, amidino, amino, cyano, hydroxyalkyl, alkoxy, alkyl, alkylamino, aminoalkyl, alkylthio, alkoxyamino, haloalkyl, haloalkoxy, and halo;
- R 2 is Z°-Q;
- Z is a covalent single bond;
- Q is selected from the group consisting of aryl and heteroaryl wherein a carbon adjacent to the carbon at the point of attachment is optionally substituted
- R , R , and R are independently selected from the group consisting of hydrido, hydroxy, amino, amidino, guanidino, lower alkylamino, alkylthio, alkoxy, alkylsulfinyl, alkylsulf onyl, amidosulfonyl, monoalkyl amidosulfonyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, carboxy, carboxamido, and cyano;
- 10 12 R and R are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkyl, alkoxy, alkoxyamino, aminoalkyl, hydroxy, amino, lower alkylamino, alkylsulfonamido, amidosulfonyl, monoalkyl amidosulfonyl, dialkyl amidosulfonyl, hydroxyalkyl, aminoalkyl, halo, haloalkyl, carboalkoxy, carboxy, carboxyalkyl, carboxyamido, and cyano;
- K is CH 2 ;
- E° is C(O)N(H);
- D , D , J , and J are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more than one is a covalent bond, K is C, no more than one of D , D , J , and J
- 5 6 5 6 5 6 5 6 5 6 5 6 is O, no more than one of D , D , J , and J is S, one of D , D , J , and J
- R , R , R , and R are independently selected from the group consisting of hydrido, amidino, guanidino, carboxy, haloalkylthio, alkoxy, hydroxy, amino, lower alkylamino, alkylthio, alkylsulfinyl, alkylsulf onyl, alkanoyl, haloalkanoyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, and cyano;
- R and R are optionally Q with the proviso that no more than one of
- R and R is Q at the same time and that Q is Q ;
- Q is selected from the group consisting of NR R , Q wherein Q is
- R , R , R , R , and R are independently selected from the group consisting of hydrido and alkyl;
- Q s is CH 2 .
- a b J and J are each O;
- B is optionally selected from the group consisting of hydrido, C2-C8 alkyl, C3-C8 alkenyl, C3-C8 alkynyl, and C2-C8 haloalkyl, wherein each member of group B is optionally substituted at any carbon up to and including
- R , R , R , R , and R are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkoxy, hydroxy, amino, alkoxyamino, lower alkylamino, alkylthio, amidosulfonyl, monoalkyl amidosulfonyl, dialkyl amidosulfonyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, carboalkoxy, carboxy, carboxamido, cyano, and Q ;
- A is selected from the group consisting of single covalent bond and
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002373610A CA2373610A1 (fr) | 1999-05-19 | 2000-05-18 | Anticoagulants a base d'uracils d'aryle polycycliques et d'heteroaryles |
MXPA01011806A MXPA01011806A (es) | 1999-05-19 | 2000-05-18 | Aril y heteroaril uracilos policiclicos sustituidos como agentes anticoagulantes. |
BR0011273-9A BR0011273A (pt) | 1999-05-19 | 2000-05-18 | Uracilas de heteroarila e arila policìclica substituìdas como agentes anti-coagulantes |
EP00931917A EP1178971A1 (fr) | 1999-05-19 | 2000-05-18 | Anticoagulants a base d'uracils d'aryle polycycliques et d'heteroaryles |
AU49724/00A AU771740B2 (en) | 1999-05-19 | 2000-05-18 | Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents |
NZ514877A NZ514877A (en) | 1999-05-19 | 2000-05-18 | Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents |
US09/979,542 US6716838B1 (en) | 1999-05-19 | 2000-05-18 | Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents |
JP2000618250A JP2002544263A (ja) | 1999-05-19 | 2000-05-18 | 抗凝血剤としての置換多環式アリールおよびヘテロアリールウラシル |
KR1020017014750A KR20010113969A (ko) | 1999-05-19 | 2000-05-18 | 항응고제로서의 치환된 폴리시클릭 아릴 및 헤테로아릴우라실 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13495799P | 1999-05-19 | 1999-05-19 | |
US60/134,957 | 1999-05-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000069833A1 true WO2000069833A1 (fr) | 2000-11-23 |
Family
ID=22465795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/008226 WO2000069833A1 (fr) | 1999-05-19 | 2000-05-18 | Anticoagulants a base d'uracils d'aryle polycycliques et d'heteroaryles |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1178971A1 (fr) |
JP (1) | JP2002544263A (fr) |
KR (1) | KR20010113969A (fr) |
CN (1) | CN1152023C (fr) |
AR (1) | AR043677A1 (fr) |
AU (1) | AU771740B2 (fr) |
BR (1) | BR0011273A (fr) |
CA (1) | CA2373610A1 (fr) |
MX (1) | MXPA01011806A (fr) |
NZ (1) | NZ514877A (fr) |
PE (1) | PE20010217A1 (fr) |
UY (1) | UY26157A1 (fr) |
WO (1) | WO2000069833A1 (fr) |
ZA (2) | ZA200109338B (fr) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001087852A1 (fr) * | 2000-05-18 | 2001-11-22 | Pharmacia Corporation | Uracils d'heteroaryle et d'aryle polycycliques substitues utiles pour l'inhibition selective de la cascade de coagulation |
WO2001055119A3 (fr) * | 2000-01-25 | 2002-02-14 | Neurocrine Biosciences Inc | Antagonistes du recepteur de la gonadoliberine et methodes associees |
US6624180B2 (en) | 2000-11-20 | 2003-09-23 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
US6653316B1 (en) | 1999-05-19 | 2003-11-25 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade |
US6660885B2 (en) | 2000-03-13 | 2003-12-09 | Pharmacia Corporation | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade |
US6664255B1 (en) | 1999-05-19 | 2003-12-16 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade |
US6686484B2 (en) | 2000-04-17 | 2004-02-03 | Pharmacia Corporation | Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade |
US6693121B2 (en) | 2000-04-05 | 2004-02-17 | Pharmacia Corporation | Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade |
US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
US6716838B1 (en) | 1999-05-19 | 2004-04-06 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents |
US6750342B1 (en) | 1999-05-19 | 2004-06-15 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade |
US6867217B1 (en) | 1999-05-19 | 2005-03-15 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade |
US6875791B2 (en) | 2000-04-05 | 2005-04-05 | Pharmacia Corporation | Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade |
US6969715B2 (en) | 2001-10-03 | 2005-11-29 | Pharmacia Corporation | 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade |
US7015230B1 (en) | 1999-05-19 | 2006-03-21 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade |
US7015223B1 (en) | 2000-11-20 | 2006-03-21 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade |
US7105559B2 (en) | 2001-10-03 | 2006-09-12 | Pharmacia Corporation | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade |
US7119094B1 (en) | 2000-11-20 | 2006-10-10 | Warner-Lambert Company | Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade |
US7157470B2 (en) | 2002-05-06 | 2007-01-02 | Bristol-Myers Squibb Company | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
US9522892B2 (en) | 2011-11-29 | 2016-12-20 | Perosphere Inc. | Anticoagulant reversal agents |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004200664B2 (en) * | 2000-01-25 | 2007-08-16 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
GB0622472D0 (en) * | 2006-11-10 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel heterocyclic derivatives |
CN116410143A (zh) * | 2021-12-29 | 2023-07-11 | 杭州奥默医药股份有限公司 | 一种多取代脲嘧啶衍生物及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996018644A1 (fr) * | 1994-12-13 | 1996-06-20 | Corvas International, Inc. | Derives aromatiques heterocycliques utilisables comme inhibiteurs d'enzymes |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA01011804A (es) * | 1999-05-19 | 2003-09-04 | Pharmacia Corp | Aril y heteroaril pirimidinonas policiclicas sustituidas utiles como anticoagulantes. |
-
2000
- 2000-05-18 AU AU49724/00A patent/AU771740B2/en not_active Ceased
- 2000-05-18 MX MXPA01011806A patent/MXPA01011806A/es unknown
- 2000-05-18 BR BR0011273-9A patent/BR0011273A/pt not_active IP Right Cessation
- 2000-05-18 NZ NZ514877A patent/NZ514877A/en unknown
- 2000-05-18 KR KR1020017014750A patent/KR20010113969A/ko not_active Application Discontinuation
- 2000-05-18 CN CNB008077533A patent/CN1152023C/zh not_active Expired - Fee Related
- 2000-05-18 CA CA002373610A patent/CA2373610A1/fr not_active Abandoned
- 2000-05-18 EP EP00931917A patent/EP1178971A1/fr not_active Withdrawn
- 2000-05-18 WO PCT/US2000/008226 patent/WO2000069833A1/fr not_active Application Discontinuation
- 2000-05-18 JP JP2000618250A patent/JP2002544263A/ja active Pending
- 2000-05-19 UY UY26157A patent/UY26157A1/es unknown
- 2000-05-19 AR ARP000102449A patent/AR043677A1/es unknown
- 2000-06-02 PE PE2000000543A patent/PE20010217A1/es not_active Application Discontinuation
-
2001
- 2001-11-13 ZA ZA200109338A patent/ZA200109338B/xx unknown
-
2004
- 2004-01-21 ZA ZA200400450A patent/ZA200400450B/xx unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996018644A1 (fr) * | 1994-12-13 | 1996-06-20 | Corvas International, Inc. | Derives aromatiques heterocycliques utilisables comme inhibiteurs d'enzymes |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6716838B1 (en) | 1999-05-19 | 2004-04-06 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents |
US6870056B1 (en) | 1999-05-19 | 2005-03-22 | Pharmacia Corporation | Substitituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade |
US6458952B1 (en) | 1999-05-19 | 2002-10-01 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade |
US6867217B1 (en) | 1999-05-19 | 2005-03-15 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade |
US7015230B1 (en) | 1999-05-19 | 2006-03-21 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade |
US6653316B1 (en) | 1999-05-19 | 2003-11-25 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade |
US6750342B1 (en) | 1999-05-19 | 2004-06-15 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade |
US6664255B1 (en) | 1999-05-19 | 2003-12-16 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade |
US7462625B2 (en) | 2000-01-25 | 2008-12-09 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
US7179815B2 (en) | 2000-01-25 | 2007-02-20 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
KR100814269B1 (ko) * | 2000-01-25 | 2008-03-18 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 고나도트로핀-분비 호르몬 수용체 길항제 및 이를 포함하는 약제학적 조성물 |
US6608197B2 (en) | 2000-01-25 | 2003-08-19 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
WO2001055119A3 (fr) * | 2000-01-25 | 2002-02-14 | Neurocrine Biosciences Inc | Antagonistes du recepteur de la gonadoliberine et methodes associees |
US6872728B2 (en) | 2000-01-25 | 2005-03-29 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
US6660885B2 (en) | 2000-03-13 | 2003-12-09 | Pharmacia Corporation | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade |
US6852761B2 (en) | 2000-03-13 | 2005-02-08 | Pharmacia Corporation | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade |
US6693121B2 (en) | 2000-04-05 | 2004-02-17 | Pharmacia Corporation | Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade |
US6916847B2 (en) | 2000-04-05 | 2005-07-12 | Pharmacia Corporation | Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade |
US6875791B2 (en) | 2000-04-05 | 2005-04-05 | Pharmacia Corporation | Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade |
US6686484B2 (en) | 2000-04-17 | 2004-02-03 | Pharmacia Corporation | Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade |
WO2001087852A1 (fr) * | 2000-05-18 | 2001-11-22 | Pharmacia Corporation | Uracils d'heteroaryle et d'aryle polycycliques substitues utiles pour l'inhibition selective de la cascade de coagulation |
US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
US6951872B2 (en) | 2000-11-06 | 2005-10-04 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
US6624180B2 (en) | 2000-11-20 | 2003-09-23 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
US7119094B1 (en) | 2000-11-20 | 2006-10-10 | Warner-Lambert Company | Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade |
US7015223B1 (en) | 2000-11-20 | 2006-03-21 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade |
US6828338B2 (en) | 2000-11-20 | 2004-12-07 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
US7105559B2 (en) | 2001-10-03 | 2006-09-12 | Pharmacia Corporation | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade |
US6969715B2 (en) | 2001-10-03 | 2005-11-29 | Pharmacia Corporation | 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade |
US7157470B2 (en) | 2002-05-06 | 2007-01-02 | Bristol-Myers Squibb Company | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
US7524863B2 (en) | 2002-05-06 | 2009-04-28 | Bristol-Myers Squibb Company | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
US9522892B2 (en) | 2011-11-29 | 2016-12-20 | Perosphere Inc. | Anticoagulant reversal agents |
US9877961B2 (en) | 2011-11-29 | 2018-01-30 | Perosphere Inc. | Anticoagulant reversal agents |
Also Published As
Publication number | Publication date |
---|---|
CN1152023C (zh) | 2004-06-02 |
JP2002544263A (ja) | 2002-12-24 |
AR043677A1 (es) | 2005-08-10 |
AU4972400A (en) | 2000-12-05 |
PE20010217A1 (es) | 2001-03-07 |
AU771740B2 (en) | 2004-04-01 |
ZA200400450B (en) | 2004-09-29 |
KR20010113969A (ko) | 2001-12-28 |
CA2373610A1 (fr) | 2000-11-23 |
CN1351594A (zh) | 2002-05-29 |
EP1178971A1 (fr) | 2002-02-13 |
MXPA01011806A (es) | 2003-09-04 |
ZA200109338B (en) | 2004-05-26 |
UY26157A1 (es) | 2000-12-29 |
BR0011273A (pt) | 2002-06-18 |
NZ514877A (en) | 2004-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6624180B2 (en) | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade | |
AU771718B2 (en) | Substituted polycyclic aryl and heteroaryl pyrymidinones useful as anticoagulants | |
AU771740B2 (en) | Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents | |
WO2000069826A1 (fr) | Pyridones aryle et heteroaryle polycycliques substituees utilisees pour l'inhibition selective de la cascade de coagulation | |
EP1202975A1 (fr) | Pyrazinones d'heteroaryle et d'aryle polycyclique substituees utiles a l'inhibition selective de la coagulation en cascade | |
US6664255B1 (en) | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | |
US6653316B1 (en) | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade | |
US6458952B1 (en) | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade | |
US6750342B1 (en) | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade | |
US7015230B1 (en) | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade | |
US6867217B1 (en) | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade | |
US7015223B1 (en) | Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade | |
US6716838B1 (en) | Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents | |
WO2001087851A1 (fr) | Aryle polycyclique substitue et pyrimidinones d'heteroaryle utiles a l'inhibition selective de la coagulation | |
US6906068B1 (en) | Substituted polycyclic aryl and heteroaryl 1,2,4 - triazinones useful as anticoagulants | |
US20040068113A1 (en) | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade | |
EP1586565A1 (fr) | Pyrazinones d'hétéroaryle et d'aryle polycyclique substituées utiles à l'inhibition selective de la coagulation en cascade | |
AU2002226902A1 (en) | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00807753.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 49724/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 514877 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2373610 Country of ref document: CA Ref document number: 2373610 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/011806 Country of ref document: MX Ref document number: 2000931917 Country of ref document: EP Ref document number: IN/PCT/2001/1598/CHE Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2000 618250 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017014750 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017014750 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000931917 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09979542 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 49724/00 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020017014750 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000931917 Country of ref document: EP |